Candel Therapeutics (NASDAQ:CADL) Trading Down 5.3%
Candel Therapeutics (NASDAQ:CADL) Trading Down 5.3%
Shares of Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) fell 5.3% during mid-day trading on Wednesday . The company traded as low as $3.20 and last traded at $3.21. 6,148 shares were traded during trading, a decline of 82% from the average session volume of 33,482 shares. The stock had previously closed at $3.39.
坎德爾治療公司(納斯達克代碼:CADL-GET評級)的股價在週三午盤交易中下跌5.3%。該公司股價低至3.20美元,最新報3.21美元。當日成交量為6,148股,較33,482股的平均日成交量下降82%。該股此前收盤價為3.39美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Separately, Credit Suisse Group lowered their price objective on shares of Candel Therapeutics to $11.00 in a research report on Monday, August 15th.
另外,瑞士信貸集團在8月15日星期一的一份研究報告中將Candel治療公司的股票目標價下調至11.00美元。
Candel Therapeutics Stock Down 5.3 %
Candel治療公司股價下跌5.3%
The company has a debt-to-equity ratio of 0.34, a quick ratio of 14.86 and a current ratio of 14.86. The stock has a market capitalization of $92.74 million, a P/E ratio of -3.96 and a beta of 0.95. The stock's fifty day simple moving average is $3.41 and its two-hundred day simple moving average is $3.81.
該公司的負債權益比率為0.34,速動比率為14.86,流動比率為14.86。該股市值為9,274萬美元,市盈率為-3.96,貝塔係數為0.95。該股的50日簡單移動均線為3.41美元,200日簡單移動均線為3.81美元。
Institutional Investors Weigh In On Candel Therapeutics
機構投資者看好Candel治療公司
Candel Therapeutics Company Profile
坎德爾治療公司簡介
(Get Rating)
(獲取評級)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Candel Treateutics,Inc.是一家臨牀階段的生物製藥公司,致力於為癌症患者開發免疫療法。該公司開發了CAN-2409,這是治療胰腺癌的第二階段臨牀試驗;治療前列腺癌的第三階段臨牀試驗;以及治療肺癌的第二階段臨牀試驗,以及治療高級別膠質瘤的Ib/II階段臨牀試驗。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Candel Therapeutics (CADL)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 免費獲取StockNews.com關於Candel治療(CADL)的研究報告
- 對塔吉特來説,最糟糕的時期可能已經過去,但這隻股票買起來安全嗎?
- 這些液態天然氣股票準備好上行了嗎?
- 內部人士正在買入的兩隻有趣的股票
- 諾華在避險市場中仍是一隻冒險的股票
- 連續60年提高股息的3只防御性股票
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《秋茄治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Candel Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。